A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BALANCE-I
- Sponsors AbbVie
- 14 Oct 2019 Results of exposure response analysis of upadacitinib using data from Phase 2 and Phase 3 rheumatoid arthritis (RA) studies published in the Clinical Pharmacology and Therapeutics
- 13 Jun 2019 Results of exposue response analysis of Upadacitinib efficacy in phase 2 trials (BALANCE-I and BALANCE-II) published in the Clinical Pharmacology and Therapeutics
- 18 May 2019 This trial has been Discontinued in Netherlands , according to European Clinical Trials Database.